Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

Tune in to hear expert faculty from the 2024 ASH Annual Meeting and Exposition take a deep dive into the latest clinical evidence and practical considerations for treatment of complex cases of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Informed by real-world data on top challenges regarding the selection, sequencing, and integration of novel therapies in DLBCL management plans, this recording of a satellite symposium supports lymphoma care teams in examining the latest evidence; differentiating new and emerging novel CAR T-cell and bispecific antibody therapies for DLBCL and FL; and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel are supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Don’t miss this opportunity to hear expert faculty harness real-world experiences providing DLBCL and FL care to deepen the impact of the education, utilizing a case-based approach to provide a basis for discussion and strategy of the optimal integration of novel therapies to enhance patient-centered care and improve outcomes in this informative satellite symposium.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/online/treatment-crossroads-diverse-perspectives-treatment-strategies-relapsed
  • Start Date: 2024-12-30 06:00:00
  • End Date: 2024-12-30 06:00:00
  • Credit Details: IPCE Credits: 1.5 hours
    AAPA Category 1 Credit™️: 1.5 hours
    AMA PRA Category 1 Credit™️: 1.5 hours
    Nursing: 1.5 hours
    Pharmacy: 1.5 hours
  • MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 3006.0 - Is Kind Support: False Source: Genmab US, Inc. - Amount: 109750.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Hematology, Medical Oncology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.